Semaglutide vs Tirzepatide
GLP-1 Receptor Agonist · Dual GIP/GLP-1 Receptor Agonist
Here is how these two compounds compare, based on published research, not marketing claims.
Semaglutide
Activates one appetite-control receptor (GLP-1). The established weight-loss and diabetes therapy with the most mature cardiovascular outcomes data.
Tirzepatide
Activates two appetite-control receptors at once (GLP-1 and GIP). The newer of the two, with the largest average weight loss in trials.
Semaglutide
4520 studies
39 human trials
FDA-Approved
Tirzepatide
1849 studies
47 human trials
FDA-Approved
What it does
Semaglutide
Holds the first FDA approval for a weekly GLP-1 drug with cardiovascular outcomes data. Marketed as Ozempic for type 2 diabetes, Wegovy for weight management, and Rybelsus as an oral tablet. Reduces appetite and slows how fast food leaves the stomach through hypothalamic GLP-1 receptor activation. Two major trials (SUSTAIN-6 in diabetic patients and SELECT in non-diabetic adults with obesity) showed reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death), not just weight or blood sugar. That cardiovascular evidence is what made the GLP-1 class category-shifting in metabolic medicine.
Tirzepatide
Activates two appetite-control receptors at once: GLP-1 and GIP. FDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound).
How it works
Semaglutide
A modified copy of GLP-1, a hormone the body releases naturally after eating. It activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full, slows how fast the stomach empties, and helps the pancreas release insulin when blood sugar is high. The modification keeps it active in the body for about a week, instead of the few minutes natural GLP-1 lasts.
Tirzepatide
Engineered to bind two natural appetite hormones' receptors at once. The GLP-1 receptor tells the brain the body is full and slows stomach emptying (the same pathway as semaglutide). The GIP receptor adds enhanced fat oxidation and improved lipid metabolism. The dual signal does what GLP-1 alone does, plus the GIP component, which appears to drive the larger weight-loss effect. Like semaglutide, it stays active in the body for about a week, allowing once-weekly dosing.
How often
Semaglutide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen for the injectable formulation. The SUSTAIN, STEP, and SELECT trial protocols used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Semaglutide is marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as a daily oral formulation for type 2 diabetes.
Tirzepatide
FDA labeling specifies once-weekly subcutaneous injection from a pre-filled pen. The SURPASS trial protocols (type 2 diabetes) and SURMOUNT trial protocols (chronic weight management) used gradual dose titration over several months, which the FDA labeling notes is associated with improved GI tolerability. Tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
How strong
Semaglutide
Strong appetite suppression. In the STEP obesity trials, average weight loss reached 15-17% at the highest dose over 68 weeks. The effect builds gradually as the dose titrates up over the first months of treatment.
Tirzepatide
The largest weight-loss effect of any FDA-approved peptide to date. In the SURMOUNT-1 trial, average weight loss reached 22.5% at the highest dose over 72 weeks. The effect builds as the dose titrates up.
Main tradeoff
Semaglutide
Strong evidence base from large completed Phase III programs (STEP for weight, SUSTAIN and PIONEER for diabetes, SELECT for cardiovascular outcomes). Common side effects are GI: nausea, vomiting, diarrhea, usually transient and dose-dependent. Tirzepatide produces larger average weight loss in head-to-head trials, but semaglutide has the longer cardiovascular outcomes data. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with tirzepatide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Tirzepatide
Larger average weight loss than semaglutide in head-to-head trials (SURPASS-2). Cardiovascular outcomes data is still maturing: semaglutide has SELECT, tirzepatide's parallel trial (SURPASS-CVOT) is ongoing. Less long-term safety data overall because tirzepatide is the newer of the two compounds. Bone mineral density may decrease modestly with significant weight loss; the effect is class-shared with semaglutide and appears weight-loss-mediated rather than drug-specific (Liu et al. 2026). Particularly relevant for adults at baseline fracture risk.
Best for
Semaglutide
- Adults with type 2 diabetes seeking glycemic control with cardiovascular outcomes data (SELECT trial)
- Adults with overweight or obesity who want the GLP-1 with the longest real-world safety record
- Clinical contexts prioritizing established cardiovascular outcomes over maximal weight reduction
Tirzepatide
- Adults with overweight or obesity seeking the largest average weight reduction available in trials
- Adults with type 2 diabetes seeking superior HbA1c reduction (SURPASS-2 head-to-head data)
- Clinical contexts willing to use a newer compound with less long-term safety data than semaglutide
How to choose
A good fit for Semaglutide
- Patients with type 2 diabetes seeking glycemic control with cardiovascular outcomes data (SELECT)
- Patients seeking the GLP-1 with the longest real-world safety record
- Clinical contexts prioritizing established cardiovascular outcomes over maximal weight reduction
A good fit for Tirzepatide
- Patients seeking the largest average weight reduction available in trial data (SURMOUNT-1)
- Patients with type 2 diabetes seeking superior HbA1c reduction (SURPASS-2 head-to-head)
- Clinical contexts willing to use a newer compound with less long-term safety data
Consider both across time
Both are FDA-approved GLP-1 medications with strong clinical trial programs. The choice isn't whether they work: both work. It's which evidence profile fits the goal. Tirzepatide has the larger average weight-loss numbers (SURMOUNT) and the head-to-head HbA1c edge in diabetes (SURPASS-2). Semaglutide has the longer cardiovascular outcomes data (SELECT) and the longer real-world safety record. Most clinical decisions come down to maximal weight reduction versus cardiovascular outcomes maturity, with tolerability and access as secondary factors.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- GLP-1 Receptor
- GLP-1 Receptor activates GLP-1 Signaling
- GLP-1 Signaling connects to Appetite + Gastric Emptying
- GLP-1 Signaling connects to Glucose Control
- Appetite + Gastric Emptying connects to Weight + Glycemic Outcomes; Glucose Control connects to Weight + Glycemic Outcomes; Appetite + Fat Metabolism connects to Weight + Glycemic Outcomes
- GIP Receptor
- GLP-1 Receptor activates Dual GIP + GLP-1 Signaling; GIP Receptor activates Dual GIP + GLP-1 Signaling
- Dual GIP + GLP-1 Signaling connects to Appetite + Fat Metabolism
Semaglutide activates the GLP-1 receptor in the brain and gut, which tells the brain the body is full and slows how fast the stomach empties.
Tirzepatide activates both GLP-1 and GIP receptors at once. The GLP-1 side mirrors semaglutide; the GIP side adds enhanced fat metabolism.
Research Evidence
Both compounds sit at the highest evidence tier (FDA Approved). Semaglutide has the deeper, longer evidence base: multiple completed Phase III programs across diabetes (SUSTAIN, PIONEER), obesity (STEP), and cardiovascular outcomes (SELECT). Tirzepatide's evidence base is substantial but newer: SURPASS for diabetes, SURMOUNT for obesity, with cardiovascular outcomes data still maturing.
- 1.
For maximal weight reduction based on trial data, tirzepatide is the closer fit. The SURMOUNT-1 program showed the largest average weight-loss numbers seen in any peptide trial.
- 2.
For glycemic control with established cardiovascular benefit, semaglutide has the SELECT trial data demonstrating cardiovascular outcomes. Tirzepatide's parallel cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
- 3.
For head-to-head HbA1c reduction at matched doses, tirzepatide outperformed semaglutide in SURPASS-2. The trial design used semaglutide 1mg, not the higher 2.4mg obesity dose, so direct efficacy comparisons at all doses remain limited.
- 4.
Both compounds require physician prescription and medical supervision. Neither should be self-selected based on efficacy claims: actual choice involves cardiovascular risk assessment, prior medication history, tolerability, and access.
Key Limitations
- •Head-to-head trials compared tirzepatide to semaglutide 1mg, not the higher 2.4mg obesity dose, making direct efficacy comparisons imperfect at all doses.
- •Long-term (5+ year) safety data is available for semaglutide but not yet for tirzepatide.
- •Individual response variability is significant for both compounds; population-level means do not predict individual outcomes.
- •Cost, insurance coverage, and supply constraints affect real-world access and may influence clinical decisions independent of efficacy data.
- •Compounded versions of both compounds are not FDA-approved and are subject to pharmacy regulations that have changed multiple times since 2023.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Semaglutide
"I lost 30+ pounds on Ozempic without changing anything else"
Supported by evidence
"Ozempic face is a real thing. I look ten years older"
Supported by evidence
"The nausea goes away after a few weeks"
Supported by evidence
Tirzepatide
"Mounjaro is stronger than Ozempic for weight loss"
Supported by evidence
"The dual agonist mechanism is why it works better"
Supported by evidence
"Tirzepatide has fewer GI side effects than semaglutide"
Plausible but limited comparison data
Safety Comparison
Both share a similar GI side effect profile: nausea, vomiting, diarrhea, usually transient and dose-dependent, manageable with slow dose titration. Semaglutide has the longer real-world safety record and more extensive post-marketing surveillance. Tirzepatide's dual-receptor mechanism is newer, and its long-term safety profile is still being characterized as more years of post-approval data accumulate. On bone density: both compounds appear to cause modest bone mineral density loss in head-to-head data (Liu et al. 2026, J Clin Endocrinol Metab), with the loss correlating with weight loss within the GLP-1 RA group rather than a direct drug effect. The pattern matches what's seen with bariatric surgery and severe caloric restriction. Fracture-outcome data is still maturing. Particularly relevant for adults at baseline fracture risk, including post-menopausal women, older adults, and anyone with prior osteopenia or osteoporosis.
Semaglutide
Well-characterized safety profile from multiple Phase III programs (STEP, SUSTAIN). Most common adverse events are GI-related: nausea, vomiting, diarrhea, typically transient and dose-dependent. Rare risks include pancreatitis and thyroid C-cell tumors (observed in rodent studies; clinical relevance debated).
Tirzepatide
Safety profile from SURPASS and SURMOUNT trials. GI adverse events similar to GLP-1 agonists but may differ in pattern due to dual-receptor activity. Long-term safety data is growing but remains less extensive than semaglutide's multi-year dataset.
What the Research Suggests
Both semaglutide and tirzepatide represent the highest evidence tier in PSI's framework. The choice isn't about whether they work: both do, with strong randomized controlled trial evidence. It's about matching mechanism, safety maturity, and outcome priority to a specific clinical question. Tirzepatide has the larger average weight-loss numbers from trials. Semaglutide has the longer cardiovascular outcomes data and the more mature real-world safety record. PSI does not endorse one compound over the other: the appropriate choice depends on the individual clinical context, which a physician evaluates.